Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Carboplatin and Megesterol Acetate in Advanced or Recurrent Endometrial Cancer
NCT00584857Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2004
- Primary completion
- Oct 2010
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, carboplatin and megestrol in endometrial cancer (EC), sponsored by University of Alabama at Birmingham. Primary endpoint: Overall Survival at 3 years. Started Jul 2004; status: completed.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatinmegestrol
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00584857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00584857.